RPG Life Sciences buys Raghava API and intermediates arm
In short
RPG Life Sciences has bought the API and intermediates business of Raghava Life Sciences for Rs 135 crore. The company says the deal fits its plan to build a bigger API-focused business.
The move could help RPG Life Sciences expand, but the reporting does not say how the deal will be paid for or when the integration will happen.
What the reporting says
RPG Life Sciences acquired the API and intermediates business of Raghava Life Sciences for Rs 135 crore. The reported rationale is consolidation under RPGAP’s buy-and-build strategy to create an API-focused organisation. The immediate operational impact, integration timetable, and any financing details are not stated in the available reporting.
Why it matters
RPG Life Sciences completed an acquisition of Raghava Life Sciences’ API and intermediates business for Rs 135 crore. The cited reason is a consolidation step under RPGAP’s buy-and-build strategy to create an API-focused organisation. The reporting does not say whether the transaction is already closed, how it will be funded, or what operational changes will follow.